Ceruloplasmin and its clinical relevance as an indactor of cardiovascular risk factor in a school population of Granada;Ceruloplasmina y su importancia clínica como factor indicador del riesgo cardiovascular en una población de escolares de Granada

Nutricion Hospitalaria

Volumn 26, Issue 3, 2011, Pages 655-658

  Aguilar Cordero, M J ^a   Gonzalez Jimenez E ^c   Perona, J S ^b   Alvarez Ferre J ^c   Padilla Lopez C A ^c   Rivas Garcia F ^d   Katarzyna, P ^c   Ocete Hita, E ^e  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b INSTITUTO DE LA GRASA   (Spain)

^c Grupo de Investigación CTS 367 P A I   (Spain)

^d Area de Salud Ayuntamiento de Guadix   (Spain)

^e UNIVERSITY OF GRANADA   (Spain)

Author keywords

Anthropometry; Cardiovascular risk; Ceruloplasmin; Overweight

Indexed keywords

CERULOPLASMIN;

ADOLESCENT; BLOOD; BODY WEIGHT; CARDIOVASCULAR DISEASE; CHILD; FEMALE; HUMAN; LETTER; MALE; OBESITY; PREDICTIVE VALUE; RISK FACTOR; SPAIN;

ADOLESCENT; BODY WEIGHT; CARDIOVASCULAR DISEASES; CERULOPLASMIN; CHILD; FEMALE; HUMANS; MALE; OBESITY; OVERWEIGHT; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SPAIN;

EID: 79957973405     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2011.26.3.5220     Document Type: Article

References (18)

1. aJ, González Jiménez E, Sánchez Perona J, Padilla López CA, Álvarez Ferre J, Mur Villar N, Rivas García F. Metodología del estudio Guadix, sobre los efectos de un desayuno tipo mediterráneo sobre los parámetros lipídicos y postprandiales en preadolescentes con sobrepeso y obesidad. Nutrición Hospitalaria 2010; 25 (6): 1025-1033.
2. Fox PL, Mazumder B, Ehrenwald E, Mukhopadhyay CK. Ceruloplasmin and cardiovascular disease. Free Radic Biol Med 2000; 28: 1735-44.
3. Hellman N, Gitlin J. Ceruloplasmin metabolism and function. Annu Rev Nutr 2002; 22: 439-58.
4. Floris G, Medda R, Padiglia A, Musci G. The physiopathological significance of ceruloplasmin: a posible therapeutic approach. Biochem Pharm 2000; 60: 1735-41.
5. Giurgea N, Constantinescu MI, Stanciu R, Suciu S, Muresan A. Ceruloplasmin acute-phase reactant or endogenous antioxidant? The case of cardiovascular disease. Med Sci Monit 2005; 11: 48-51.
6. Shukla N, Maher J, Masters J, Angelini GD, Jeremy JY. Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor? Atherosclerosis 2006; 187: 238-50.
7. Xu H, Barnes GT, Yang Q y cols. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-30.
8. Uriu JY, Keen CL. Copper, oxidative stress, and human health. Mol Aspects Med 2005; 26: 268-98.
9. Kim CH, Park JY, Kim JY y cols. Elevated serum ceruloplasmin levels in subjects with metabolic syndrome: a populationbased study. Metabolism 2002; 51: 838-42.
10. Cignarelli M, DePergola G, Picca G, Sciaraffia M, Pannacciulli N, Tarallo M, Laudadio E, Turrisi E, Giorgino R. Relationship of obesity and body fat distribution with ceruloplasmin serum levels. Int J Obes Relat Metab Disord 1996; 20 (9): 809-13.
11. Exner M, Hermann M, Hofbauer R, Hartmann B, Kapiotis S, Gmeiner B. Homocysteine promotes the LDL oxidase activity of ceruloplasmin. FEBS Lett 2002; 531: 402-6.
12. Danzeisen, R, Araya, M, Harrison, B, Keen, C, Solioz, M, Thiele, D & McArdle, HJ. How reliable and robust are current biomarkers for copper status? Br J Nutr 2007; 98: 676-83.
13. Harvey LJ, McArdle HJ. Biomarkers of copper status: a brief update. Br J Nutr 2008; 99 (Suppl. 3): S10-S3.
14. Bertinato J, Zouzoulas A. Considerations in the development of biomarkers of copper status. J AOAC Int 2009; 92 (5): 1541-50.
15. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000; 320: 1240-43.
16. Engström G, Hedblad B, Stavenow L, Jonsson S, Lind P, Janzon L, Lindgärde F. Incidence of obesity-associated cardiovascular disease is related to inflammation-sensitive plasma proteins: a population-based cohort study. Arterioscler Throm Vasc Biol 2004; 24 (8): 1498-502.
17. Wärnberg J, Nova E, Moreno LA, Romeo J, Mesana MI, Ruíz JR, Ortega FB, Sjöström M, Bueno M, Marcos A, AVENA Study Group. Inflammatory proteins are related to total and abdominal adiposity in a healthy adolescent population: the AVENA Study. Am J Clin Nutr 2006; 84 (3): 505-12.
18. Zulet MA, Puchau B, Navarro C, Martí A, Martínez JA. Inflammatory biomarkers: the link between obesity and associated pathologies. Nutr Hosp 2007; 22 (5): 511-27.